Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy

Yi Fan Chen, Li Hsien Chen, Yu-Min Yeh, Pei-Ying Wu, Yih Fung Chen, Lian Yun Chang, Jang-Yang Chang, Meng-Ru Shen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer treatment. No medication has been shown to be effective in the treatment of CIPN. This study aims to integrate the image-based high-content screening, mouse behavior models and mechanistic cell-based assays to discover potential neuroprotective drugs. Among screened compounds, minoxidil showed the most potent neuroprotective effect against paclitaxel, with regard to neurite outgrowth of dorsal root ganglia (DRG). Minoxidil protected mice from thermal insensitivity and alleviated mechanical allodynia in paclitaxel-treated mice. The ultrastructure and quantified G-ratio of myelin integrity of sciatic nerve tissues supported the observations in mouse behavioral tests. The mechanistic study on DRG neurons suggested that minoxidil suppressed neuroinflammation and remodeled the dysregulation of intracellular calcium homeostasis provoked by paclitaxel. Importantly, minoxidil showed a synergistic anti-tumor effect with paclitaxel both in tumor xenograft models of cervical and breast cancer. Interestingly, the quantitative assays on hair length and hair growth both exhibited that minoxidil significantly improved the hair quality after chemotherapy. Since minoxidil is a drug approved by the Food and Drug Administration (FDA), the safety and biocompatibility are well documented. The immediate next step is to launch an early-stage clinical trial intending to prevent CIPN by minoxidil.

Original languageEnglish
Article number45366
JournalScientific reports
Volume7
DOIs
Publication statusPublished - 2017 Mar 28

Fingerprint

Minoxidil
Neuroprotective Agents
Peripheral Nervous System Diseases
Paclitaxel
Hair
Drug Therapy
Spinal Ganglia
Nerve Tissue
Neoplasms
Hyperalgesia
Sciatic Nerve
United States Food and Drug Administration
Myelin Sheath
Heterografts
Uterine Cervical Neoplasms
Homeostasis
Hot Temperature
Clinical Trials
Breast Neoplasms
Calcium

All Science Journal Classification (ASJC) codes

  • General

Cite this

@article{54d61d42e7ca48ff87afcdf853c8aab1,
title = "Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy",
abstract = "Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer treatment. No medication has been shown to be effective in the treatment of CIPN. This study aims to integrate the image-based high-content screening, mouse behavior models and mechanistic cell-based assays to discover potential neuroprotective drugs. Among screened compounds, minoxidil showed the most potent neuroprotective effect against paclitaxel, with regard to neurite outgrowth of dorsal root ganglia (DRG). Minoxidil protected mice from thermal insensitivity and alleviated mechanical allodynia in paclitaxel-treated mice. The ultrastructure and quantified G-ratio of myelin integrity of sciatic nerve tissues supported the observations in mouse behavioral tests. The mechanistic study on DRG neurons suggested that minoxidil suppressed neuroinflammation and remodeled the dysregulation of intracellular calcium homeostasis provoked by paclitaxel. Importantly, minoxidil showed a synergistic anti-tumor effect with paclitaxel both in tumor xenograft models of cervical and breast cancer. Interestingly, the quantitative assays on hair length and hair growth both exhibited that minoxidil significantly improved the hair quality after chemotherapy. Since minoxidil is a drug approved by the Food and Drug Administration (FDA), the safety and biocompatibility are well documented. The immediate next step is to launch an early-stage clinical trial intending to prevent CIPN by minoxidil.",
author = "Chen, {Yi Fan} and Chen, {Li Hsien} and Yu-Min Yeh and Pei-Ying Wu and Chen, {Yih Fung} and Chang, {Lian Yun} and Jang-Yang Chang and Meng-Ru Shen",
year = "2017",
month = "3",
day = "28",
doi = "10.1038/srep45366",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy. / Chen, Yi Fan; Chen, Li Hsien; Yeh, Yu-Min; Wu, Pei-Ying; Chen, Yih Fung; Chang, Lian Yun; Chang, Jang-Yang; Shen, Meng-Ru.

In: Scientific reports, Vol. 7, 45366, 28.03.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy

AU - Chen, Yi Fan

AU - Chen, Li Hsien

AU - Yeh, Yu-Min

AU - Wu, Pei-Ying

AU - Chen, Yih Fung

AU - Chang, Lian Yun

AU - Chang, Jang-Yang

AU - Shen, Meng-Ru

PY - 2017/3/28

Y1 - 2017/3/28

N2 - Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer treatment. No medication has been shown to be effective in the treatment of CIPN. This study aims to integrate the image-based high-content screening, mouse behavior models and mechanistic cell-based assays to discover potential neuroprotective drugs. Among screened compounds, minoxidil showed the most potent neuroprotective effect against paclitaxel, with regard to neurite outgrowth of dorsal root ganglia (DRG). Minoxidil protected mice from thermal insensitivity and alleviated mechanical allodynia in paclitaxel-treated mice. The ultrastructure and quantified G-ratio of myelin integrity of sciatic nerve tissues supported the observations in mouse behavioral tests. The mechanistic study on DRG neurons suggested that minoxidil suppressed neuroinflammation and remodeled the dysregulation of intracellular calcium homeostasis provoked by paclitaxel. Importantly, minoxidil showed a synergistic anti-tumor effect with paclitaxel both in tumor xenograft models of cervical and breast cancer. Interestingly, the quantitative assays on hair length and hair growth both exhibited that minoxidil significantly improved the hair quality after chemotherapy. Since minoxidil is a drug approved by the Food and Drug Administration (FDA), the safety and biocompatibility are well documented. The immediate next step is to launch an early-stage clinical trial intending to prevent CIPN by minoxidil.

AB - Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer treatment. No medication has been shown to be effective in the treatment of CIPN. This study aims to integrate the image-based high-content screening, mouse behavior models and mechanistic cell-based assays to discover potential neuroprotective drugs. Among screened compounds, minoxidil showed the most potent neuroprotective effect against paclitaxel, with regard to neurite outgrowth of dorsal root ganglia (DRG). Minoxidil protected mice from thermal insensitivity and alleviated mechanical allodynia in paclitaxel-treated mice. The ultrastructure and quantified G-ratio of myelin integrity of sciatic nerve tissues supported the observations in mouse behavioral tests. The mechanistic study on DRG neurons suggested that minoxidil suppressed neuroinflammation and remodeled the dysregulation of intracellular calcium homeostasis provoked by paclitaxel. Importantly, minoxidil showed a synergistic anti-tumor effect with paclitaxel both in tumor xenograft models of cervical and breast cancer. Interestingly, the quantitative assays on hair length and hair growth both exhibited that minoxidil significantly improved the hair quality after chemotherapy. Since minoxidil is a drug approved by the Food and Drug Administration (FDA), the safety and biocompatibility are well documented. The immediate next step is to launch an early-stage clinical trial intending to prevent CIPN by minoxidil.

UR - http://www.scopus.com/inward/record.url?scp=85016620308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016620308&partnerID=8YFLogxK

U2 - 10.1038/srep45366

DO - 10.1038/srep45366

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 45366

ER -